Mana.bio
(https://mana.bio) 📸 Data Snapshot: May 31, 2026
Information Density — The Lens
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Info Density
Power-words vs. Substance ratio.
22
Impact Weight: 30 / 100
73% Reputation
The information density is relatively high for a startup, with specific technical nouns like ‘lipid nanoparticles,’ ‘in silico’ modeling, and ‘high-throughput screening’ anchoring the claims. However, fluff persists in headings like ‘The technology’ and the body text’s reliance on power words such as ‘pioneering,’ ‘disrupt,’ and ‘unprecedented possibilities.’ The substance is found in the description of their LNP AI Agent ‘Mina’ and the specific output metric of ‘dozens of lipid nanoparticle formulations per week.’
Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.
📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE (https://mana.bio) Programmable Drug Delivery | Mana.bio
[IMG: Small-Polygons-Header.png] [IMG: Manabio logo] Mana.bio is an AI based drug delivery startup, focusing on gene therapy including DNA and RNA-based therapeutics, and vaccines. We are on a mission to disrupt the drug delivery space using combined forces of machine learning and nanotechnology.Vision [H2] Drug Delivery [IMG: Drug Delivery] [IMG: Drug Delivery] [IMG: Machine Learning] [IMG: Machine Learning] [IMG: Machine Learning] [H2] Machine Learning [IMG: Nanotechnology] [IMG: Nanotechnology] [IMG: Nanotechnology] [H2] Nanotechnology Technology [IMG: polygon-techs-3.png] [H4] The technology The technology is powered by an integration of machine learning and nanotechnology in order to identify formulations of lipid nanoparticles drug delivery systems.Read More [IMG: Machine learning and nanotechnology illustration] [H4] ChatLNP - LNP AI Agent Mana introduces Mina, the first AI Agent built specifically for lipid nanoparticles. Quickly explore curated literature, predict LNP properties, and optimize formulations. Mina empowers scientists, formulation experts, and biotech teams to move faster and better. Try Mina now [IMG: BG-Gree.png] [IMG: 124915.jpg] [H4] The team Mana is founded and led by a team of repeat entrepreneurs and highly regarded experts in the field of drug delivery, machine learning and software development which are inspired by the potential of combining advanced technologies in biology and medicine.Meet the Team
1457 chars
SUB-PAGE (https://mana.bio/technology/) Technology | Mana.bio
[IMG: Small-Polygons-Header.png] At Mana.bio, we are pioneering a new era in genetic medicine through our unique integration of machine learning and lipid nanoparticle (LNP) design. [IMG: genetic medicine] Our AI-driven approach transcends traditional limitations, enabling precise and optimized formulations for extrahepatic delivery of nucleic acid therapeutics and vaccines. By harnessing the power of AI to significantly cut down the time for development and to achieve novel IP-protected results, we are not only advancing the field of gene therapy but also unlocking unprecedented possibilities for collaborations and innovations in the biotech and pharmaceutical industries. [IMG: Circle] [H4] Mana.bio Platform desin [IMG: Design] [H4] Design Mana.bio's AI platform designs novel lipid nanoparticle candidates in silico using its machine learning models that predict desirable properties to select best-in-class cell specific tissue-targeted LNPs. [IMG: Rectanglles.png] Built [H4] Build Mana.bio uses its high-throughput capabilities to synthesize and make dozens of lipid nanoparticle formulations per week, transforming computational models into physical entities using automated manufacturing pipelines. [IMG: lipid nanoparticle formulations] Test [IMG: lipid nanoparticle formulations] [H4] Test Mana.bio thoroughly evaluates each constructed lipid nanoparticle through automated, high-throughput screening infrastructure including assays that analyze efficacy, safety and physicochemical properties to identify top candidates, while continuously generating data to further improve the machine learning models predictions. [IMG: Rectanglles.png] Learn [H4] Learn [H2] All experimental results are digitally stored and instantly transferred into the AI platform training set. This is how the machine learning models are improved on a weekly basis. In addition, the Mana.bio automation platform continuously leverages publicly available data with its unique software tools and so enriching the ever growing proprietary database that constantly improves its AI models' ability to design tissue-targeted LNPs [IMG: lipid nanoparticle formulations]
2158 chars
SUB-PAGE (https://mana.bio/team/) Team
Mana.bio is a seed stage biotech company leveraging data, machine learning and high throughput screening to design novel LNPs for targeted extrahepatic delivery of nucleic acid therapeutics and vaccines.Mana is founded and led by a team of repeat entrepreneurs and highly regarded experts in the field of drug delivery, machine learning and software development which are inspired by the potential of combining advanced technologies in biology and medicine. [H4] Founders [H2] Yogev Debbi Co-Founder & CEORepeat biotech entrepreneur, experienced in business leadership and applying software technologies in biology applications.Read More [H2] Roy Nevo Co-Founder & CTO Repeat biotech entrepreneur and a veteran software architect, skilled at leading rapidly developing innovative biotech products.Read More [H2] Prof. Avi Schroeder Scientific co-founderNanomedicine and drug delivery expert; Tenured Professor in the Chemical Engineering faculty at the Technion.Read More [H2] Dr. Kira Radinsky Scientific co-founderAI and data science expert pioneering predictive data mining and its applications in medicine.Read More [H4] Advisory Board [H2] Cory Sago, PhD Biomedical engineer and serial entrepreneur experienced in discovering lipid nanoparticles for targeted RNA delivery.Read More [H2] Peter Nell, PhD Experienced biopharma executive with over 20 years of experience advancing gene editing programs from R&D through commercialization.Read More [H2] Gaurav Sahay, PhD Expert in developing nanotechnology-based platforms for effective mRNA therapeutics, particularly for cystic fibrosis and retinal degeneration.Read More [H2] Barry Ticho, MD PhD Experienced drug developer and clinician leading multiple neurology and cardiology programs through clinical trials and commercializationRead More [H2] Prof. Eitan Kerem, MD Pediatric specialist and researcher who has made substantial contributions to improving cystic fibrosis patient care and advocacy.Read More [H2] Guy Van Meter Guy Van Meter is the CBO at Adimab, where he scaled the $5B+ antibody leader via 140+ major partnerships. He formerly led Pfizer’s RNA Business Development.Read More [H2] Prof. Jordan Green Prolific biomedical engineer, professor, and entrepreneur developing innovative genetic medicines and immunotherapies.Read More [H2] Lubo Nechev, PhD Renowned expert in RNAi therapeutics and lipid nanoparticle formulation with a proven track record in developing innovative solutions for gene delivery.Read More [H4] Investors [IMG: Nfx logo.png] [IMG: LionBird Logo.png] [IMG: a16z logo.png] [IMG: base4 logo small.png] [IMG: TRDF LOGO.JPG] [IMG: image.png] Using Mana’s proprietary platform we aim to create novel delivery solutions that will unlock the RNA and nucleic acid therapeutics potential, and treat genetic diseases across a wide range of unmet needs.
2849 chars
SUB-PAGE · THIN (https://mana.bio/fto/) LNP patents map | Mana.bio
[IMG: Mana bio FTO map v3.gif]
30 chars
🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes, pioneering medical science, the future of medicine…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified, patient testimonials making efficacy claims, off-label promotion signals…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations, specific patent numbers and status, pharmacovigilance and adverse event reporting mechanisms…
Explore the other reputation pillars for Mana.bio
Analysis Disclosure & Source Attribution
This page presents a snapshot of public data from Mana.bio, captured on May 31, 2026, to show how machine logic reads Information Density signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Mana.bio: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://mana.bio to view the most current version of its content and see directly what this company is about and what it offers.